We are live on ! Find out more
MBII

Marrone Bio Innovations, Inc.
MBII

Delisted

MBII was delisted on the 12th of July, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Marrone Bio Innovations, Inc. in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 62 → 0 (-62)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $45M → $0 (-$45M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 62

Holders
–
Holders Change
-62
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
62
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AAP
Ardsley Advisory Partners
Connecticut
-$21.3M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$4.64M
3
SC
Shay Capital
New York
-$2.49M
4
GLAM
Gardner Lewis Asset Management
Pennsylvania
-$2.32M
5
Primecap Management
Primecap Management
California
-$1.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
LP
26
LMR Partners
United Kingdom
– -$56K -48,156 Closed
BCV
27
Banque Cantonale Vaudoise
Switzerland
– -$53K -46,115 Closed
HF
28
HRT Financial
New York
– -$44K -38,542 Closed
YIH
29
Y-Intercept (HK)
Hong Kong
– -$42K -36,537 Closed
BFM
30
Boothbay Fund Management
New York
– -$42K -36,057 Closed
Victory Capital Management
31
Victory Capital Management
Texas
– -$28K -24,334 Closed
Balyasny Asset Management
32
Balyasny Asset Management
Illinois
– -$27K -23,350 Closed
DC
33
Diametric Capital
Massachusetts
– -$26K -22,590 Closed
KLCM
34
KG&L Capital Management
Louisiana
– -$26K -22,500 Closed
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
– -$24.4K -21,060 Closed
FIA
36
FNY Investment Advisers
New York
– -$23K -20,000 Closed
Creative Planning
37
Creative Planning
Kansas
– -$20K -16,855 Closed
PCM
38
Prelude Capital Management
New York
– -$14K -11,705 Closed
9WM
39
9258 Wealth Management
Ohio
– -$12K -10,764 Closed
AWM
40
Apollon Wealth Management
South Carolina
– -$12K -10,000 Closed
AWM
41
Avior Wealth Management
Nebraska
– -$11K -10,000 Closed
BG
42
Bahl & Gaynor
Ohio
– -$12K -10,000 Closed
Cetera Investment Advisers
43
Cetera Investment Advisers
Illinois
– -$12K -10,000 Closed
Northwestern Mutual Wealth Management
44
Northwestern Mutual Wealth Management
Wisconsin
– -$12K -10,000 Closed
CSS
45
Cubist Systematic Strategies
Connecticut
– -$11K -9,288 Closed
Citigroup
46
Citigroup
New York
– -$9K -8,046 Closed
Legal & General Group
47
Legal & General Group
United Kingdom
– -$9K -7,972 Closed
Osaic Holdings
48
Osaic Holdings
Arizona
– -$7K -6,031 Closed
Wells Fargo
49
Wells Fargo
California
– -$4K -3,558 Closed
TRCT
50
Tower Research Capital (TRC)
New York
– -$3K -2,181 Closed
1
2
3

MBII Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Marrone Bio Innovations, Inc. (MBII) for Q3 2022, worth a combined $0 — down 100% from $45M a quarter earlier.

Sellers outnumbered buyers: 62 funds closed out of MBII and 0 opened new positions — a net loss of 62 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $21.3M sold.

  • 0 institutional investors held Marrone Bio Innovations, Inc. (MBII) as of Q3 2022, down from 62 in Q2 2022.
  • Funds reported $0 of Marrone Bio Innovations, Inc. stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Marrone Bio Innovations, Inc. positions in Q3 2022 and 62 closed out, a net change of -62 holders.
  • The largest Marrone Bio Innovations, Inc. seller in Q3 2022 was Ardsley Advisory Partners, an estimated $21.3M sold.

Based on aggregated 13F filings for Q3 2022.